Clinical trial · Interventional
Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma
NCT00241020CI-TRIAL-00021711completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hepatocellular carcinoma (HCC) is one of the most common malignant disease worldwide with an increasing incidence in industrialized countries. For patients with advanced HCC no efficient treatment is currently available. The objective of this study is to assess the efficacy and safety of octreotide in patients with advanced hepatocellular carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Octreotide | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Octreotide
- interventionNames
- Drug: Octreotide
Primary outcomes (1)
- measure
- Overall Survival
Secondary outcomes (6)
- measure
- Objective response
- measure
- Survival without progression
- measure
- Digestive bleeding
- measure
- Renal insufficiency
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * \> 18 years * HCC diagnosis : * histologically or cytologically proven HCC * or association of the three following criteria: * cirrhosis * typical measurable mass (\> 3cm, by 2 methods) * serum alpha-foetoprotein (AFP) ≥500 µg/L * Cancer Liver Italian Program (CLIP) score : 0 to 3 * Not eligible for specific treatment (surgery, percutaneous ablation or chemo-embolization) Exclusion Criteria: * Glycemia \> 2.5 g/L or hypoglycemia * Extra hepatic life-threatening disease * Serum creatinin\> 120 µmol/L * Prothrombin time \< 50 % * Platelet count \< 50.000 /µL * Symptomatic cholelithiasis * Non-measurable tumor
References
Publications (0)
Data not yet available
No reference posted for this study.